287 related articles for article (PubMed ID: 31141829)
41. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
42. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.
Coltin H; Perreault S; Larouche V; Black K; Wilson B; Vanan MI; Gupta AA; Morgenstern DA; Parkin PC; Bouffet E; Ramaswamy V
Pediatr Blood Cancer; 2022 Aug; 69(8):e29633. PubMed ID: 35289492
[TBL] [Abstract][Full Text] [Related]
43. Peripheral nerve tumors in neurofibromatosis 1: An overview on management and indications for surgical treatment in our experience.
Garozzo D
Neurol India; 2019; 67(Supplement):S38-S44. PubMed ID: 30688231
[TBL] [Abstract][Full Text] [Related]
44. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.
Perrin GQ; Fishbein L; Thomson SA; Thomas SL; Stephens K; Garbern JY; DeVries GH; Yachnis AT; Wallace MR; Muir D
J Neurosci Res; 2007 May; 85(6):1347-57. PubMed ID: 17335073
[TBL] [Abstract][Full Text] [Related]
45. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019.
Collins-Sawaragi YC; Ferner R; Vassallo G; De Agrò G; Eccles S; Cadwgan J; Hargrave D; Hupton E; Eelloo J; Lunt L; Tang V; Burkitt Wright E; Lascelles K
Am J Med Genet A; 2022 Jun; 188(6):1723-1727. PubMed ID: 35178860
[TBL] [Abstract][Full Text] [Related]
46. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
[TBL] [Abstract][Full Text] [Related]
47. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
[No Abstract] [Full Text] [Related]
49. Selumetinib for children with plexiform neurofibromas.
Burki TK
Lancet Oncol; 2017 Feb; 18(2):e69. PubMed ID: 28089105
[No Abstract] [Full Text] [Related]
50. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
[TBL] [Abstract][Full Text] [Related]
51. Intra-parotid facial nerve multiple plexiform neurofibroma in patient with NF1.
Fadda MT; Verdino G; Mustazza MC; Bartoli D; Iannetti G
Int J Pediatr Otorhinolaryngol; 2008 May; 72(5):553-7. PubMed ID: 18329107
[TBL] [Abstract][Full Text] [Related]
52. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
[TBL] [Abstract][Full Text] [Related]
53. Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1.
Leonard JR; Ferner RE; Thomas N; Gutmann DH
J Neurol Neurosurg Psychiatry; 2007 Dec; 78(12):1404-6. PubMed ID: 17635968
[TBL] [Abstract][Full Text] [Related]
54. Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience.
Kokkinou E; Roka K; Alexopoulos A; Tsina E; Nikas I; Krallis P; Thanopoulou I; Nasi L; Makrygianni E; Tsoutsou E; Kosma K; Tsipi M; Tzetis M; Frysira H; Kattamis A; Pons R
Postgrad Med; 2019 Sep; 131(7):445-452. PubMed ID: 31443616
[TBL] [Abstract][Full Text] [Related]
55. Biallelic inactivation of NF1 in a sporadic plexiform neurofibroma.
Beert E; Brems H; Renard M; Ferreiro JF; Melotte C; Thoelen R; De Wever I; Sciot R; Legius E; Debiec-Rychter M
Genes Chromosomes Cancer; 2012 Sep; 51(9):852-7. PubMed ID: 22585738
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
[TBL] [Abstract][Full Text] [Related]
57. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
[TBL] [Abstract][Full Text] [Related]
58. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
[TBL] [Abstract][Full Text] [Related]
59. Surgical Management of "Kissing" Spinal Plexiform Neurofibromas in Neurofibromatosis Type 1 Patients.
Shofty B; Mauda-Havakuk M; Ben-Sira L; Bokstein F; Lidar Z; Salame K; Korn A; Constantini S
World Neurosurg; 2020 Feb; 134():e1143-e1147. PubMed ID: 31786384
[TBL] [Abstract][Full Text] [Related]
60. Response of NF1-related plexiform neurofibroma to high-dose carboplatin.
Hummel T; Anyane-Yeboa A; Mo J; Towbin A; Weiss B
Pediatr Blood Cancer; 2011 Mar; 56(3):488-90. PubMed ID: 21225936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
